142 related articles for article (PubMed ID: 37418973)
1. Discovery of new Lenalidomide derivatives as potent and selective GSPT1 degraders.
Wei Y; Xu X; Jiang M; Wang Y; Zhou Y; Wang Z; Zhang Z; Zhou F; Ding K
Eur J Med Chem; 2023 Oct; 258():115580. PubMed ID: 37418973
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel GSPT1 degraders by virtual screening and bioassay.
Zhang S; Nie S; Ma G; Shen M; Kong L; Zuo Z; Li Y
Eur J Med Chem; 2024 Jul; 273():116524. PubMed ID: 38795517
[TBL] [Abstract][Full Text] [Related]
3. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective.
Chang X; Qu F; Li C; Zhang J; Zhang Y; Xie Y; Fan Z; Bian J; Wang J; Li Z; Xu X
Med Res Rev; 2024 Jul; 44(4):1727-1767. PubMed ID: 38314926
[TBL] [Abstract][Full Text] [Related]
4. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationship analysis of novel GSPT1 degraders based on benzotriazinone scaffold and its antitumor effect on xenograft mouse model.
Takwale AD; Kim EY; Jang Y; Lee DH; Kim S; Choi Y; Kim JH; Lee DY; Kim Y; Lee SM; Lee HK; Nam HJ; Lee JY; Cho JH; Moon JH; Lee GS; Kim JH; Kim P; Park CH; Hwang JY
Bioorg Chem; 2022 Oct; 127():105923. PubMed ID: 35717803
[TBL] [Abstract][Full Text] [Related]
6. Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells.
Sellar RS; Sperling AS; Słabicki M; Gasser JA; McConkey ME; Donovan KA; Mageed N; Adams DN; Zou C; Miller PG; Dutta RK; Boettcher S; Lin AE; Sandoval B; Quevedo Barrios VA; Kovalcik V; Koeppel J; Henderson EK; Fink EC; Yang L; Chan A; Pokharel SP; Bergstrom EJ; Burt R; Udeshi ND; Carr SA; Fischer ES; Chen CW; Ebert BL
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35763353
[TBL] [Abstract][Full Text] [Related]
7. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein.
Hegde R; Srinivasula SM; Datta P; Madesh M; Wassell R; Zhang Z; Cheong N; Nejmeh J; Fernandes-Alnemri T; Hoshino S; Alnemri ES
J Biol Chem; 2003 Oct; 278(40):38699-706. PubMed ID: 12865429
[TBL] [Abstract][Full Text] [Related]
8. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
Nishiguchi G; Keramatnia F; Min J; Chang Y; Jonchere B; Das S; Actis M; Price J; Chepyala D; Young B; McGowan K; Slavish PJ; Mayasundari A; Jarusiewicz JA; Yang L; Li Y; Fu X; Garrett SH; Papizan JB; Kodali K; Peng J; Pruett Miller SM; Roussel MF; Mullighan C; Fischer M; Rankovic Z
J Med Chem; 2021 Jun; 64(11):7296-7311. PubMed ID: 34042448
[TBL] [Abstract][Full Text] [Related]
9. Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.
Ishoey M; Chorn S; Singh N; Jaeger MG; Brand M; Paulk J; Bauer S; Erb MA; Parapatics K; Müller AC; Bennett KL; Ecker GF; Bradner JE; Winter GE
ACS Chem Biol; 2018 Mar; 13(3):553-560. PubMed ID: 29356495
[TBL] [Abstract][Full Text] [Related]
10. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
[TBL] [Abstract][Full Text] [Related]
11. G1 to S phase transition protein 1 induces apoptosis signal-regulating kinase 1 activation by dissociating 14-3-3 from ASK1.
Lee JA; Park JE; Lee DH; Park SG; Myung PK; Park BC; Cho S
Oncogene; 2008 Feb; 27(9):1297-305. PubMed ID: 17700517
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of the eukaryotic release factor 3 (eRF3/GSPT1) according to gastric cancer histological types.
Malta-Vacas J; Aires C; Costa P; Conde AR; Ramos S; Martins AP; Monteiro C; Brito M
J Clin Pathol; 2005 Jun; 58(6):621-5. PubMed ID: 15917414
[TBL] [Abstract][Full Text] [Related]
13. Protein Degradation via CRL4
Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
[TBL] [Abstract][Full Text] [Related]
14. Molecular glues targeting GSPT1 in cancers: A potent therapy.
Zhang D; Lin P; Lin J
Bioorg Chem; 2024 Feb; 143():107000. PubMed ID: 38029571
[TBL] [Abstract][Full Text] [Related]
15. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
16. A Novel Rac1-GSPT1 Signaling Pathway Controls Astrogliosis Following Central Nervous System Injury.
Ishii T; Ueyama T; Shigyo M; Kohta M; Kondoh T; Kuboyama T; Uebi T; Hamada T; Gutmann DH; Aiba A; Kohmura E; Tohda C; Saito N
J Biol Chem; 2017 Jan; 292(4):1240-1250. PubMed ID: 27941025
[TBL] [Abstract][Full Text] [Related]
17. Identification of GSPT1 as prognostic biomarker and promoter of malignant colon cancer cell phenotypes via the GSK-3β/CyclinD1 pathway.
Long X; Zhao L; Li G; Wang Z; Deng Z
Aging (Albany NY); 2021 Apr; 13(7):10354-10368. PubMed ID: 33819920
[TBL] [Abstract][Full Text] [Related]
18. The role of miR-144/GSPT1 axis in gastric cancer.
Tian QG; Tian RC; Liu Y; Niu AY; Zhang J; Gao WF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(13):4138-4145. PubMed ID: 30024602
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies against human translation termination factor eRF3 and their utilization for sub-cellular localization of eRF3.
Delage MM; Dutertre S; Le Guével R; Frolova L; Berkova N
J Biochem; 2011 Jul; 150(1):49-59. PubMed ID: 21421683
[TBL] [Abstract][Full Text] [Related]
20. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
